Immunic CEO Dr Daniel Vitt on Successful 2024, With More to Come in the Year Ahead | NASDAQ:IMUX

Proactive InvestorsDec 13 21:00

Immunic CSO Discusses Breaking the IBD Stigma to Mark Crohn's and Colitis Awareness Week | NASDAQ:IMUX

Proactive InvestorsDec 2 17:15

B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6

Futu NewsNov 26 14:32 · Ratings

Immunic's Promising Pipeline Progress and Stable Financials Justify Buy Rating

TipRanksNov 26 14:05 · Ratings

Immunic, Inc. to Participate in Investor Conference in December

ImmunicNov 26 13:00

Immunic Price Target Announced at $10.00/Share by HC Wainwright & Co.

Dow JonesNov 25 21:35 · Ratings